Sign In
Buy PBM
$3.17
-0.190 (-5.65%)
At Close: Jul 31, 2026
CVS Sues Arkansas Over Law Banning PBM Ownership Of Pharmacies
06:30pm, Thursday, 29'th May 2025
CVS Health Thursday sued the state of Arkansas, trying to thwart a law the healthcare company said would lead to the closure of all 23 CVS drugstores in the state.
Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial
07:30am, Tuesday, 27'th May 2025
New York, New York--(Newsfile Corp. - May 27, 2025) - Psyence BioMed (NASDAQ: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company developing nature-derived psilocybin therapies for u
CVS Health Stock Rallies 38% in May: Is it a Buy Amid PBM Pressure?
04:01pm, Wednesday, 14'th May 2025
CVS' pharmacy segment continues to lead the industry, processing over 1.7 billion prescriptions annually while delivering high medication adherence.
Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split
07:30am, Thursday, 01'st May 2025
New York, New York--(Newsfile Corp. - May 1, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced the effective date of its 1-for-7.97 share consolidation
Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
07:17pm, Thursday, 17'th Apr 2025
New York, New York--(Newsfile Corp. - April 17, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") announced today that it received a notification letter dated April 16,
Psyence Group Announces Share Consolidation
09:39am, Thursday, 17'th Apr 2025
TORONTO, April 17, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc. ("Psyence Group" or the "Company") (CSE: PSYG), announces that the Company will be consolidating all of its issued and outstanding share
Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement
08:30am, Tuesday, 15'th Apr 2025
New York, New York--(Newsfile Corp. - April 15, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced a strategic follow-on investment of USD $500,000 into
Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia
08:00am, Tuesday, 08'th Apr 2025
New partnership strengthens Psyence BioMed's global clinical trial capabilities, accelerating the development of psilocybin-assisted therapy for adjustment disorder New York, New York--(Newsfile Corp.
Company executives will host a corporate webinar for investors and stakeholders on Thursday, April 10, 2025 New York, New York--(Newsfile Corp. - March 31, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM
Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein
08:30am, Tuesday, 18'th Mar 2025
Appointment adds significant clinical and scientific expertise in the field of psychedelic-based therapies New York, New York--(Newsfile Corp. - March 18, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM)
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D.
11:18am, Monday, 10'th Mar 2025
TORONTO, March 10, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or
Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D.
08:00am, Wednesday, 26'th Feb 2025
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it will work closely with Albert P.
CVS's stock soars after a big profit beat, continued improvement in PBM business
08:07am, Wednesday, 12'th Feb 2025
CVS's stock soared toward a three-month high after its quarterly profit beat expectations by the widest margin in more than four years.
Psyence Biomed Announces Closing of $2.0 Million Private Placement
04:05pm, Friday, 27'th Dec 2024
NEW YORK, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has closed its previously announced private placem
Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements
07:30am, Monday, 23'rd Dec 2024
Company poised to enter 2025 with cash position of $5.6 million and debt-free balance sheet Company poised to enter 2025 with cash position of $5.6 million and debt-free balance sheet
